false Q2 --12-31 0001859007 0001859007 2024-01-01 2024-06-30 0001859007 2024-08-08 0001859007 2024-06-30 0001859007 2023-12-31 0001859007 us-gaap:SeriesAPreferredStockMember 2024-06-30 0001859007 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001859007 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001859007 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001859007 2024-04-01 2024-06-30 0001859007 2023-04-01 2023-06-30 0001859007 2023-01-01 2023-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001859007 us-gaap:CommonStockMember 2023-12-31 0001859007 us-gaap:TreasuryStockCommonMember 2023-12-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001859007 us-gaap:RetainedEarningsMember 2023-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-03-31 0001859007 us-gaap:CommonStockMember 2024-03-31 0001859007 us-gaap:TreasuryStockCommonMember 2024-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001859007 us-gaap:RetainedEarningsMember 2024-03-31 0001859007 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001859007 us-gaap:CommonStockMember 2022-12-31 0001859007 us-gaap:TreasuryStockCommonMember 2022-12-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001859007 us-gaap:RetainedEarningsMember 2022-12-31 0001859007 2022-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-03-31 0001859007 us-gaap:CommonStockMember 2023-03-31 0001859007 us-gaap:TreasuryStockCommonMember 2023-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001859007 us-gaap:RetainedEarningsMember 2023-03-31 0001859007 2023-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001859007 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001859007 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001859007 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001859007 2024-01-01 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-06-30 0001859007 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001859007 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001859007 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-03-31 0001859007 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001859007 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001859007 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001859007 2023-01-01 2023-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-06-30 0001859007 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001859007 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001859007 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-06-30 0001859007 us-gaap:CommonStockMember 2024-06-30 0001859007 us-gaap:TreasuryStockCommonMember 2024-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001859007 us-gaap:RetainedEarningsMember 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001859007 us-gaap:CommonStockMember 2023-06-30 0001859007 us-gaap:TreasuryStockCommonMember 2023-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001859007 us-gaap:RetainedEarningsMember 2023-06-30 0001859007 2023-06-30 0001859007 2023-12-04 2023-12-04 0001859007 2024-04-25 2024-04-25 0001859007 us-gaap:SubsequentEventMember 2024-08-01 2024-08-01 0001859007 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001859007 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001859007 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001859007 ZVSA:SeriesAConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001859007 ZVSA:SeriesAConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001859007 ZVSA:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001859007 ZVSA:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001859007 ZVSA:InflamacoreLlcLicenseAgreementMember 2024-06-30 0001859007 ZVSA:InflamacoreLlcLicenseAgreementMember 2023-06-30 0001859007 2024-06-30 2024-06-30 0001859007 2024-07-01 2024-07-01 0001859007 ZVSA:LicenseAgreementMember ZVSA:LAndFResearchLLCMember 2023-02-28 2023-02-28 0001859007 ZVSA:LicenseAgreementMember ZVSA:LAndFResearchLLCMember ZVSA:WaiverAMember 2023-02-28 2023-02-28 0001859007 ZVSA:LicenseAgreementMember ZVSA:LAndFResearchLLCMember ZVSA:WaiverBMember 2023-02-28 2023-02-28 0001859007 ZVSA:LicenseAgreementMember ZVSA:LAndFResearchLLCMember ZVSA:WaiverAMember 2023-03-29 2023-03-29 0001859007 ZVSA:LicenseAgreementMember ZVSA:LAndFResearchLLCMember ZVSA:WaiverAMember 2023-03-29 0001859007 ZVSA:LicenseAgreementMember ZVSA:LAndFResearchLLCMember ZVSA:WaiverBMember 2024-01-30 2024-01-30 0001859007 2019-01-18 0001859007 2019-01-18 2019-01-18 0001859007 ZVSA:LeaseCommitmentMember 2024-01-15 2024-01-15 0001859007 ZVSA:MarketingAgreementsMember 2024-01-01 2024-06-30 0001859007 ZVSA:MarketingAgreementsMember 2024-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember 2024-03-06 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember 2024-02-26 2024-03-06 0001859007 ZVSA:PreFundedWarrantsMember us-gaap:InvestorMember 2024-02-23 0001859007 2023-02-20 0001859007 srt:MinimumMember 2023-01-01 2023-06-30 0001859007 srt:MaximumMember 2023-01-01 2023-06-30 0001859007 ZVSA:ExercisePriceOneMember 2024-06-30 0001859007 ZVSA:ExercisePriceOneMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceTwoMember 2024-06-30 0001859007 ZVSA:ExercisePriceTwoMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceThreeMember 2024-06-30 0001859007 ZVSA:ExercisePriceThreeMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceFourMember 2024-06-30 0001859007 ZVSA:ExercisePriceFourMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceFiveMember 2024-06-30 0001859007 ZVSA:ExercisePriceFiveMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceSixMember 2024-06-30 0001859007 ZVSA:ExercisePriceSixMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceSevenMember 2024-06-30 0001859007 ZVSA:ExercisePriceSevenMember 2024-01-01 2024-06-30 0001859007 ZVSA:December2023PreFundedWarrantsMember 2024-06-30 0001859007 ZVSA:December2023PreFundedWarrantsMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceOneMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceOneMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceTwoMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceTwoMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceThreeMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceThreeMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceFourMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceFourMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceFiveMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceFiveMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceSixMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceSixMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceSevenMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceSevenMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:ExercisePriceEightMember us-gaap:WarrantMember 2024-06-30 0001859007 ZVSA:ExercisePriceEightMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 us-gaap:WarrantMember 2024-06-30 0001859007 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember 2024-08-01 2024-08-01 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember ZVSA:CommonStockOneMember 2024-08-01 2024-08-01 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember ZVSA:CommonStockTwoMember 2024-08-01 2024-08-01 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember ZVSA:CommonStockOneMember 2024-08-01 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember ZVSA:CommonStockTwoMember 2024-08-01 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-08-01 0001859007 us-gaap:CommonStockMember ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember 2024-08-01 2024-08-01 0001859007 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-08-09 0001859007 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-08-01 0001859007 ZVSA:DecemberTwoThousandTwentyThreeOfferingMember us-gaap:SubsequentEventMember 2024-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2024

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______

 

Commission File Number: 001-41184

 

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   86-2685744

(State or other jurisdiction

of incorporation or organization)

   (I.R.S. Employer
Identification No.)
     

2200 N. Commerce Parkway, Suite 208

Weston, FL 33326

  

 

33326

(Address of registrant’s principal executive offices)   (Zip Code)
     
(754) 231-1688
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   ZVSA   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes: ☒ No: ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes: ☒ No: ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: ☐ No: ☒

 

As of August 8, 2024, the number of shares outstanding of the registrant’s common stock, $0.0001 par value per share, was 1,029,196.

 

Except as otherwise indicated, all share and per share information in this Report gives effect to the reverse stock split of the registrant’s outstanding common stock at a ratio of one-for-ten shares, which was effected as of 4:01 p.m. Eastern Time on April 25, 2024.

 

 

 

 
 

 

ZYVERSA THERAPEUTICS, INC.

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

PART I FINANCIAL INFORMATION 1
   
Item 1. Financial Statements 1
   
Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1
   
Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and June 30, 2023 2
   
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and June 30, 2023 3
   
Unaudited Condensed Consolidated Statements of Cash flows for the Six Months Ended June 30, 2024 and June 30, 2023 4
   
Notes to Unaudited Condensed Consolidated Financial Statements 5
   
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 14
   
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk. 23
   
ITEM 4. Controls and Procedures. 23
   
PART II - OTHER INFORMATION 24
   
ITEM 1. Legal Proceedings. 24
   
ITEM 1A. Risk Factors. 24
   
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds. 24
   
ITEM 3. Defaults Upon Senior Securities. 24
   
ITEM 4. Mine Safety Disclosures. 24
   
ITEM 5. Other Information. 24
   
ITEM 6. Exhibits. 25
   
SIGNATURES 26

 

 
 

 

PART I FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ZYVERSA THERAPEUTICS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   June 30,   December 31, 
   2024   2023 
   (Unaudited)     
Assets        
         
Current Assets:          
Cash  $119,486   $3,137,674 
Prepaid expenses and other current assets   521,906    215,459 
Total Current Assets   641,392    3,353,133 
Equipment, net   1,733    6,933 
In-process research and development   18,647,903    18,647,903 
Vendor deposit   178,476    98,476 
Operating lease right-of-use asset   -    7,839 
Total Assets  $19,469,504   $22,114,284 
Liabilities and Stockholders’ Equity          
Current Liabilities:          
Accounts payable  $8,316,506   $8,431,583 
Accrued expenses and other current liabilities   1,678,322    1,754,533 
Operating lease liability   -    8,656 
Total Current Liabilities   9,994,828    10,194,772 
Deferred tax liability   854,621    844,914 
Total Liabilities   10,849,449    11,039,686 
           
Commitments and contingencies (Note 6)   -    - 
Stockholders’ Equity:          
Preferred stock, $0.0001 par value, 1,000,000 shares authorized:          
Series A preferred stock, 8,635 shares designated, 50 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively   -    - 
Series B preferred stock, 5,062 shares designated, 5,062 shares issued and outstanding as of June 30, 2024 and December 31, 2023   1    1 
Common stock, $0.0001 par value, 250,000,000 shares authorized;        
834,903 and 405,212 shares issued at June 30, 2024 and December 31, 2023, respectively, and 834,896 and 402,205 shares outstanding as of June 30, 2024 and December 31, 2023, respectively   83    40 
Additional paid-in-capital   117,436,743    114,300,849 
Accumulated deficit   (108,809,604)   (103,219,124)
Treasury stock, at cost, 7 shares at June 30, 2024 and December 31, 2023, respectively   (7,168)   (7,168)
Total Stockholders’ Equity   8,620,055    11,074,598 
           
Total Liabilities and Stockholders’ Equity  $19,469,504   $22,114,284 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

1
 

 

ZYVERSA THERAPEUTICS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2024   2023   2024   2023 
  

For the Three Months Ended

June 30,

  

For the Six Months Ended

June 30,

 
   2024   2023   2024   2023 
Operating Expenses:                    
Research and development  $709,049   $1,220,576   $1,221,987   $2,276,519 
General and administrative   2,044,929    3,929,225    4,358,627    7,465,362 
Impairment of in-process research and development   -    69,280,171    -    69,280,171 
Impairment of goodwill   -    11,895,033    -    11,895,033 
Total Operating Expenses   2,753,978    86,325,005    5,580,614    90,917,085 
Loss From Operations   (2,753,978)   (86,325,005)   (5,580,614)   (90,917,085)
                     
Other (Income) Expense:                    
Interest (income) expense   58    314    159    (765)
                     
Pre-Tax Net Loss   (2,754,036)   (86,325,319)   (5,580,773)   (90,916,320)
Income tax (provision) benefit   (9,707)   7,812,226    (9,707)   8,859,277 
Net Loss   (2,763,743)   (78,513,093)   (5,590,480)   (82,057,043)
Deemed dividend to preferred stockholders   -    (7,915,836)   -    (7,915,836)
Net Loss Attributable to Common Stockholders  $(2,763,743)  $(86,428,929)  $(5,590,480)  $(89,972,879)
                     
Net Loss Per Share                    
- Basic and Diluted  $(3.31)  $(1,694.12)  $(7.67)  $(2,329.76)
Weighted Average Number of Common Shares Outstanding                    
- Basic and Diluted   834,915    51,017    729,306    38,619 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2
 

 

ZYVERSA THERAPEUTICS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

 

For The Three and Six Months Ended June 30, 2024 and 2023

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   For the Three and Six Months Ended June 30, 2024 
  

Series A

Preferred Stock

  

Series B

Preferred Stock

   Common Stock   Treasury Stock  

Additional

Paid-In

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
                                             
Balance - December 31, 2023   50   $       -    5,062   $     1    405,212   $   40    (7)  $(7,168)  $  114,300,849   $  (103,219,124)  $ 11,074,598 
Exercise of warrants   -    -    -    -    213,800    21    -    -    2,672,479    -    2,672,500 
Exercise of pre-funded warrants   -    -    -    -    131,481    13    -    -    (13)   -    - 
Issuance of common stock pursuant to vendor agreements   -    -    -    -    9,000    1    -    -    79,199    -    79,200 
Round up share adjustment due to reverse split   -    -    -    -    75,410    8    -    -    (8)   -    - 
Stock-based compensation   -    -    -    -    -    -    -    -    223,573    -    223,573 
Net loss   -    -    -    -    -    -    -    -    -    (2,826,737)   (2,826,737)
Balance - March 31, 2024   50    -    5,062    1    834,903    83    (7)   (7,168)   117,276,079    (106,045,861)   11,223,134 
Stock-based compensation   -    -    -    -    -    -    -    -    160,664    -    160,664 
Net loss   -    -    -    -    -    -    -    -    -    (2,763,743)   (2,763,743)
Balance - June 30, 2024   50   $-    5,062   $1    834,903   $83    (7)  $(7,168)  $117,436,743   $(108,809,604)  $8,620,055 

 

   For the Three and Six Months Ended June 30, 2023 
  

Series A

Preferred Stock

  

Series B

Preferred Stock

   Common Stock   Treasury Stock  

Additional

Paid-In

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
                                             
Balance - December 31, 2022   8,635   $      1    5,062   $     1   $  25,760   $       3    -    -    104,584,170    (4,921,178)     99,662,997 
Reclassification of formerly redeemable common stock   -    -    -    -    188    -    -    -    331,331    -    331,331 
Issuance of common stock pursuant to vendor agreements   -    -    -    -    371    -    -    -    395,200    -    395,200 
Registration costs associated with preferred stock issuance   -    -    -    -    -    -    -    -    (34,674)   -    (34,674)
Stock-based compensation   -    -    -    -    -    -    -    -    287,461    -    287,461 
Net loss   -    -    -    -    -    -    -    -    -    (3,543,950)   (3,543,950)
                                                        
Balance - March 31, 2023   8,635    1    5,062    1    26,319    3    -    -    105,563,488    (8,465,128)   97,098,365 
Registered offering of common stock [1]   -    -    -    -    31,473    3    -    -    9,831,016    -    9,831,019 
Redemption of Series A Preferred Stock   (8,400)   (1)   -    -    -    -    -    -    (10,080,000)   -    (10,080,001)
Conversion of Series A Preferred Stock into common stock   (35)   -    -    -    50    -    -    -    -    -    - 
Shares issued as consideration for extension of lock-up period   -    -    -    -    8,698    1    -    -    1,156,777    -    1,156,778 
Issuance of common stock pursuant to vendor agreements   -    -    -    -    1,086    -    -    -    210,000    -    210,000 
Stock-based compensation   -    -    -    -    -    -    -    -    365,742    -    365,742 
Treasury stock acquired, at cost   -    -    -    -    -    -    (7)   (7,168)   -    -    (7,168)
Net loss   -    -    -    -    -    -    -    -    -    (78,513,093)   (78,513,093)
                                                        
Balance - June 30, 2023   200   $-    5,062   $1    67,626   $7    (7)  $(7,168)  $  107,047,023   $(86,978,221)  $20,061,642 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3
 

 

ZYVERSA THERAPEUTICS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2024   2023 
   For the Six Months Ended June 30, 
   2024   2023 
         
Cash Flows From Operating Activities:          
Net loss  $(5,590,480)  $(82,057,043)
Adjustments to reconcile net loss to net cash used in operating activities:          
Impairment of in-process research and development   -    69,280,171 
Impairment of goodwill   -    11,895,033 
Stock-based compensation   384,237    653,203 
Issuance of common stock pursuant to vendor agreements   79,200    605,200 
Shares issued as consideration for extension of lock-up period   -    1,156,778 
Depreciation of fixed assets   5,200    5,200 
Non-cash rent expense   7,839    44,473 
Deferred tax provision (benefit)   9,707    (8,882,516)
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   (306,447)   (661,564)
Security deposit   -    46,659 
Vendor deposits   (80,000)   235,000 
Accounts payable   (115,077)   2,118,388 
Operating lease liability   (8,656)   (49,131)
Accrued expenses and other current liabilities   (76,211)   613,077 
Net Cash Used In Operating Activities   (5,690,688)   (4,997,072)
           
           
Cash Flows From Financing Activities:          
Proceeds from issuance of common stock in public offering   -    11,015,500 
Registration and issuance costs associated with common stock issuance   -    (1,213,657)
Redemption of Series A Preferred Stock   -    (10,465,610)
Exercise of warrants   2,672,500    - 
Purchase of treasury stock   -    (7,168)
Registration and issuance costs associated with preferred stock issuance   -    (5,500)
           
Net Cash Provided By (Used In) Financing Activities   2,672,500    (676,435)
           
Net Decrease in Cash   (3,018,188)   (5,673,506)
           
Cash - Beginning of Period   3,137,674    5,902,199 
           
Cash - End of Period  $119,486   $228,693 
           
Supplemental Disclosures of Cash Flow Information:          
Reclassification of formerly redeemable common stock  $-   $331,331 
Accounts payable for deferred offering costs  $-   $44,892 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Note 1 – Business Organization, Nature of Operations and Basis of Presentation

 

Organization and Operations

 

ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024 and as amended on May 15, 2024.

 

On December 4, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2023 Reverse Split.

 

On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split.

 

Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2023 Reverse Split and the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented. See Note 7 – Stockholders’ Permanent and Temporary Equity – Reverse Stock Split.

 

5
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Note 2 - Going Concern and Management’s Plans

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

As of June 30, 2024, the Company had cash of approximately $0.1 million and a working capital deficit of approximately $9.3 million. During the six months ended June 30, 2024, the Company incurred a net loss of approximately $5.6 million and used cash in operations of approximately $5.7 million. The Company has an accumulated deficit of approximately $108.8 million as of June 30, 2024.

 

The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

 

Consequently, the Company will be required to raise additional funds through equity or debt financing. On August 1, 2024, the Company received approximately $0.8 million upon the exercise of warrants. See Note 8 – Subsequent Events – Stock Warrants for additional details. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

 

Note 3 – Summary of Significant Accounting Policies

 

Since the date the Company’s December 31, 2023 financial statements were issued in its 2023 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies.

 

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

 

6
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Net Loss Per Common Share

 

Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period.

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

  

   2024   2023 
   As of June 30, 
   2024   2023 
Warrants [1]   689,293    67,835 
Options   9,671    10,243 
Series A Convertible Preferred Stock   72    286 
Series B Convertible Preferred Stock   2,067    2,067 
Total potentially dilutive shares   701,103    80,431 

 

[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.

 

Segment Reporting

 

The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

 

Reclassifications

 

Certain prior period balances have been reclassified from security deposits to vendor deposits on the condensed consolidated balance sheet in order to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.

 

7
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Note 4 – Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following as of June 30, 2024 and December 31, 2023:

  

   June 30,   December 31, 
   2024   2023 
         
L&F milestone payment liability  $-   $500,000 
Payroll accrual   731,717    668,803 
Other accrued expenses   21,969    41,969 
Bonus accrual   917,375    536,500 
Registration delay liability [1]   7,261    7,261 
Total accrued expenses and other current liabilities  $1,678,322   $1,754,533 

 

[1]See Note 7 - Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

 

Note 5 – Income Taxes

 

Income tax expense and the effective tax rate were as follows:

  

(in thousands)  2024   2023 
   For the Six Months Ended 
   June 30, 
(in thousands)  2024   2023 
         
Income tax (expense) benefit  $(9,707)  $8,859,277 
           
Effective tax rate   (0.17)%   9.70%

 

The tax provisions for the six months ended June 30, 2024 and 2023 were computed using the estimated effective tax rates applicable to the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision, as necessary. The Company’s effective tax rate was (0.17)% and 9.7% for the six months ended June 30, 2024 and 2023. The decrease in the quarterly rates is primarily the result of the Company recording a full valuation allowance during the six months ended June 30, 2024 due to the reversal of a significant deferred tax liability that existed as of June 30, 2023.

 

Note 6 – Commitments and Contingencies

 

Litigations, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable.

 

8
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Disputed Vendor Invoices

 

On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice consisted of miscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing these invoices and has requested the vendor to rescind each of them. Given that the invoices are being disputed, the Company has not accrued for these invoices as of June 30, 2024.

 

License Agreements

 

L&F Research LLC

 

The Company entered into a License Agreement with L&F Research LLC (“L&F Research”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis.

 

On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). Waiver A was contingent upon (i) forgiveness by the Company of $351,579 in aggregate principal amount outstanding under a certain convertible note, and (ii) a cash payment by the Company to L&F in the amount of $648,421, on or before March 31, 2023. Waiver B was contingent upon a cash payment by the Company to L&F in the amount of $500,000 on or before the earlier of (x) January 31, 2024, and (y) ten business days from the date that the Company received net proceeds of at least $30,000,000 from the issuance of new equity capital. All other terms of the L&F License remain in effect.

 

On March 29, 2023, the Company paid the $648,421 of cash to L&F, thus meeting the conditions of Waiver A, which also had the effect of canceling the Note Receivable and the Put Option and resulted in a reclassification of 188 shares of common stock and $331,331 classified as temporary equity to permanent equity.

 

On January 30, 2024, the Company paid $500,000 of cash to L&F, thus meeting the conditions of Waiver B.

 

Operating Leases

 

On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and increases approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months.

 

The Company recognized right-of-use asset amortization of $0 and $7,839 in connection with its operating lease for the three and six months ending June 30, 2024 and the Company recognized rent expense of $43,271 and $84,743 in connection with its operating lease for the three and six months ending June 30, 2024.

 

The Company recognized right-of-use amortization of $38,783 and $77,198 in connection with its operating lease for the three and six months ending June 30, 2023, respectively.

 

9
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

A summary of the Company’s right-of-use assets and liabilities is as follows:

  

   2024   2023 
   For the Six Months Ended 
   June 30, 
   2024   2023 
         
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows used in operating activities  $8,656   $49,130 
           
Right-of-use assets obtained in exchange for lease obligations          
Operating leases  $-   $- 
           
Weighted Average Remaining Lease Term          
Operating leases   -    0.59 Years 
           
Weighted Average Discount Rate          
Operating leases   -    6.5%

 

Note 7 – Stockholders’ Permanent and Temporary Equity

 

Reverse Stock Split

 

On April 25, 2024, the Company effected the 2024 Reverse Split. Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split. See Note 1 – Business Organization, Nature of Operations and Basis of Presentation for additional details.

 

Common Stock

 

During the six months ended June 30, 2024, the Company entered into a marketing agreement with a vendor in which the Company issued an aggregate of 9,000 shares of common stock and cash in exchange for marketing services. The $79,200 fair value of the common stock was established as a prepaid expense and the Company will recognize the expense over the terms of the contracts.

 

Temporary Equity

 

See Note 6 – Commitments and Contingencies for discussion of the movement of temporary equity to permanent equity on March 29, 2023.

 

Stock-Based Compensation

 

For the three months ended June 30, 2024 the Company recorded stock-based compensation expense of $160,664 (of which, $15,447 was included in research and development and $145,217 was included in general and administrative expense) related to options issued to employees and consultants. For the three months ended June 30, 2023 the Company recorded stock-based compensation expense of $365,742 (of which, $109,066 was included in research and development and $256,676 was included in general and administrative expense) related to options issued to employees and consultants.

 

10
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

For the six months ended June 30, 2024 the Company recorded stock-based compensation expense of $384,237 (of which, $30,895 was included in research and development and $353,342 was included in general and administrative expense) related to options issued to employees and consultants. For the six months ended June 30, 2023 the Company recorded stock-based compensation expense of $653,203 (of which, $158,521 was included in research and development and $494,682 was included in general and administrative expense) related to options issued to employees and consultants. As of June 30, 2024 there was $643,224 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.4 years.

 

Stock Options

 

The grant date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:

  

   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
Fair value of common stock on date of grant  N/A   $0.44   N/A   $0.44 - $2.23 
Risk free interest rate  N/A    3.76%  N/A    3.53% - 4.27%
Expected term (years)  N/A    6.00   N/A    6.00 
Expected volatility  N/A    122%  N/A    120% - 123%
Expected dividends  N/A    0.00%  N/A    0.00%

 

A summary of the option activity for the six months ended June 30, 2024 is presented below:

  

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
                 
Outstanding, January 1, 2024   10,243   $2,218.51                  
Granted   -    -           
Exercised   -    -           
Expired   (572)   1,760.50           
Outstanding, June 30, 2024   9,671   $2,245.60    5.8   $- 
                     
Exercisable, June 30, 2024   6,823   $2,979.56    5.9   $- 

 

11
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

The following table presents information related to stock options as of June 30, 2024:

  

Options Outstanding    Options Exercisable 
           Weighted      
      Outstanding    Average    Exercisable 
Exercise    Number of    Remaining Life    Number of 
Price    Options    In Years    Options 
$152.50    4,157    8.9    1,674 
$738.50    286    8.6    95 
$791.00    38    8.7    12 
$1,760.50    1,338    2.3    1,338 
$3,965.50    37    8.0    37 
$4,053.00    2,095    4.8    2,095 
$5,726.00    1,720    6.9    1,572 
      9,671    5.9    6,823 

 

Stock Warrants

 

Between February 26, 2024 and March 6, 2024, investors in the December 2023 Offering exercised warrants to purchase 213,800 shares of common stock at an exercise price of $12.50 per share for total proceeds of $2,672,500.

 

Between January 17 and February 23, 2024, a December 2023 Offering investor exercised pre-funded warrants to purchase 131,500 shares of common stock on a cashless basis to purchase 131,481 shares of common stock at an exercise price of $0.001 per share.

 

A summary of the warrant activity for the six months ended June 30, 2024, is presented below:

  

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Warrants   Price   In Years   Value 
                 
Outstanding, January 1, 2024 [1]   903,320   $123.44                     
Issued   -    -           
Forfeited   (227)   4,053.00           
Exercised [2]   (213,800)   12.50           
Outstanding, June 30, 2024   689,293   $156.64    3.42   $- 
                     
Exercisable, June 30, 2024   689,093   $156.17    3.42   $- 

 

[1]Warrants outstanding exclude 131,500 December 2023 Pre-Funded Warrants outstanding with an exercise price of $0.001.

 

[2]Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.

 

12
 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

The following table presents information related to stock warrants as of June 30, 2024:

  

Warrants Outstanding    Warrants Exercisable 
      Outstanding    Weighted Average    Exercisable  
Exercise    Number of    Remaining Life    Number of 
Price    Warrants    In Years    Warrants 
$12.50    586,200    3.33    586,200 
$47.50    20,347    4.70    20,347 
$57.75    19,965    4.02    19,965 
$350.00    27,551    3.83    27,551 
$700.00    13,944    3.45    13,944 
$1,760.50    300    0.19    100 
$2,415.00    3,651    3.45    3,651 
$4,025.00    17,335    3.45    17,335 
      689,293    3.42    689,093 

 

Effectiveness Failure

 

In connection with the business combination with Larkspur Health Acquisition Corp., the Company conducted the Series A Preferred Stock Financing. On or about February 20, 2023, the Company failed to have the SEC declare a registration statement effective (the “Effectiveness Failure”) which covered the Series A Preferred Stock registrable securities within the time period prescribed by the Securities Purchase Agreement (the “SPA”). The SPA entitles the investors to receive registration delay payments (“Registration Delay Payments”) equal to 1.5% of each investor’s purchase price on the date of the Effectiveness Failure and every thirty days thereafter that the Effectiveness Failure persists. Failure to make the Registration Delay Payments on a timely basis result in the accrual of interest at the rate of 2.0% per month. On April 28, 2023, the proceeds from the April 2023 Offering were used to make most of the Registration Delay Payments and redeem substantially all of the Series A Preferred Stock. As of June 30, 2024, the Company has accrued additional Registration Delay Payments of approximately $7,261 in the aggregate.

 

Note 8 – Subsequent Events

 

Stock Warrants

 

On August 1, 2024, the Company initiated a limited time program, which was immediately accepted by the warrant holder, that permitted the holder to exercise its December 2023 Offering warrants at a reduced exercise price of $3.46 per share and granted new warrants to purchase (i) 392,000 shares of common stock with an exercise term of 5 years from stockholder approval and (ii) 86,600 shares of common stock with an exercise term of 18 months from stockholder approval. Both warrants have an exercise price of $3.46 per share. Under the program, the warrant holder submitted an exercise notice and the related aggregate cash exercise price to purchase 239,300 shares of common stock on August 1, 2024 for gross proceeds of $827,978. However, due to beneficial ownership limitations, only 194,300 of the 239,300 shares of common stock have been issued through the filing date. The remaining 45,000 unissued shares of common stock and the related exercise proceeds are held in abeyance pending availability under the beneficial ownership limitations. Issuance costs include financial advisor fees of $50,000 and reimbursement to the financial advisor for legal expenses.

 

13
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of the results of operations and financial condition of ZyVersa Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those financial statements that are included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis should be read in conjunction with the Company’s audited financial statements and related disclosures as of December 31, 2023 and for the year then ended, which are included in the Form 10-K (the “Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024, as amended on May 15, 2024. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains statements that are forward-looking. These statements are based on current expectations and assumptions that are subject to risk, uncertainties and other factors. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue,” and similar expressions or variations. Actual results could differ materially because of the factors discussed in “Risk Factors” in our Annual Report, and other factors that we may not know. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements above, to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q.

 

Business Overview

 

We are a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux MediatorTM VAR 200. The lead indication for IC 100 is obesity and its associated metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion.

 

Financial Operations Overview

 

We have not generated any revenue to date and have incurred significant operating losses. Our net losses were $5.6 million for the period from January 1, 2024 through June 30, 2024, compared to $82.1 million for the period from January 1, 2023 through June 30, 2023. As of June 30, 2024, we had an accumulated deficit of approximately $108.8 million and cash of $0.1 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses. We expect our expenses will increase in connection with our ongoing activities as we:

 

  ● progress development of VAR 200 and IC 100;
     
  ● prepare and file regulatory submissions;
     
  ● begin to manufacture our product candidates for clinical trials;
     
  ● hire additional research and development, finance, and general and administrative personnel;
     
  ● protect and defend our intellectual property; and
     
  ● meet the requirements of being a public company.

 

We will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include government grants and collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

 

14
 

 

Components of Operating Results

 

Revenue

 

Since inception, we have not generated any revenue and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements.

 

Operating Expenses

 

Research and Development Expenses

 

Research and development expenses consist of costs incurred in the discovery and development of our product candidates, and primarily include:

 

  ● expenses incurred under third party agreements with contract research organizations (“CROs”), and investigative sites, that conducted or will conduct our clinical trials and a portion of our pre-clinical activities;
     
  ● costs of raw materials, as well as manufacturing cost of our materials used in clinical trials and other development testing;
     
  ● expenses, including salaries, stock-based compensation and benefits of employees engaged in research and development activities;
     
  ● costs of equipment, depreciation and other allocated expenses; and
     
  ● fees paid for contracted regulatory services as well as fees paid to regulatory authorities including the U.S. Food and Drug Administration (the “FDA”) for review and approval of our product candidates.

 

We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid expenses or accrued expenses.

 

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue clinical development for our product candidates. As products enter later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Historically, our research and development costs have primarily related to the development of VAR 200 and IC 100. As we advance VAR 200 and IC 100, as well as identify any other potential product candidates, we will continue to allocate our direct external research and development costs to the products. We expect to fund our research and development expenses from our current cash and cash equivalents and any future equity or debt financings, or other capital sources, including potential collaborations with other companies or other strategic transactions.

 

15
 

 

The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including:

 

  ● the number of clinical sites included in the clinical trials;
     
  ● the length of time required to enroll suitable patients;
     
  ● the size of patient populations participating in the clinical trials;
     
  ● the number of doses a patient receives;
     
  ● the duration of patient follow-ups;
     
  ● the development state of the product candidates; and
     
  ● the efficacy and safety profile of the product candidates.

 

Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals, and the expense of filing, prosecuting, defending and enforcing any patent claims or other intellectual property rights. We may never succeed in achieving regulatory approval for our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of our product candidates. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Product commercialization will take several years and likely millions of dollars in development costs.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries, stock-based compensation and related costs for our employees in administrative, executive and finance functions. General and administrative expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, human resource, information technology, office, and travel expenses.

 

We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and potential commercialization of our product candidates. We also expect to incur substantial expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services, director and officer insurance, and investor and public relations costs.

 

16
 

 

Results of Operations

 

Comparison of the three months ended June 30, 2024 and the three months ended June 30, 2023

 

The following table summarizes our results of operations for the three months ended June 30, 2024 and for the three months ended June 30, 2023.

 

  

For the Three Months Ended

June 30,

  

Favorable

(Unfavorable)

 
(in thousands)  2024   2023   $ Change   % Change 
Operating expenses:                    
Research and development  $709   $1,221   $512    41.9%
General and administrative   2,045    3,929    1,884    48.0%
Impairment of in-process research and development   -    69,280    69,280    100.0%
Impairment of goodwill   -    11,895    11,895    100.0%
Total Operating Expenses   2,754    86,325    83,571    96.8%
                     
Loss from Operations   (2,754)   (86,325)   83,571    96.8%
                     
Other Income (Expense), Net   -    -    -    - 
                     
Pre-tax net loss   (2,754)   (86,325)   83,571    96.8%
Income tax benefit   (10)   7,812    (7,822)   (100.0%)
Net loss  $(2,764)  $(78,513)  $75,749    96.5%

 

Research and development expenses

 

Research and development expenses were approximately $0.7 million for the three months ended June 30, 2024, a decrease of approximately $0.5 million or 41.9% from the three months ended June 30, 2023. The decrease is primarily attributable to a decrease of $0.4 million in the costs of manufacturing of IC 100 and a decrease in payroll expenses due to employee attrition of $0.1 million.

 

General and administrative expenses

 

General and administrative expenses were approximately $2.0 million for the three months ended June 30, 2024, a decrease of approximately $1.9 million or 48.0% from the three months ended June 30, 2023. The decrease is primarily attributable to $1.2 million of common stock granted to certain members of Larkspur Health LLC, a Delaware limited liability company (the “Sponsor”), recognized in 2023 in exchange for increasing the duration of the period during which they are not permitted to sell their common stock, a $0.2 million decrease in professional fees due to reduced fees related to changes in public auditors and legal counsel, a $0.2 million decrease in marketing costs for investor and public relations as a result of a reduction in marketing vendors in 2024, a $0.2 million decrease in director and officer insurance due to reduced costs in the second year of being a public company, and a $0.1 million decrease in stock-based compensation as a result of options becoming fully amortized in February 2024.

 

Impairment of In-Process Research and Development and Goodwill

 

For the three months ended June 30, 2023, impairment of in-process research and development and impairment of goodwill were $69.3 million and $11.9 million, respectively. The impairment was a result of the decline in stock value and market capitalization of the Company at June 30, 2023. There was no impairment for the three months ended June 30, 2024.

 

17
 

 

Comparison of the six months ended June 30, 2024 and the six months ended June 30, 2023

 

The following table summarizes our results of operations for the six months ended June 30, 2024 and for the six months ended June 30, 2023.

 

  

For the Six Months Ended

June 30,

  

Favorable

(Unfavorable)

 
(in thousands)  2024   2023   $ Change   % Change 
Operating expenses:                    
Research and development  $1,222   $2,277   $1,055    46.3%
General and administrative   4,358    7,465    3,107    41.6%
Impairment of in-process research and development   -    69,280    69,280    100.0%
Impairment of goodwill   -    11,895    11,895    100.0%
Total Operating Expenses   5,580    90,917    85,337    93.9%
                     
Loss from Operations   (5,580)   (90,917)   85,337    93.9%
                     
Other Income (Expense), Net   -    1    (1)   (100.0%)
                     
Pre-tax net loss   (5,580)   (90,916)   85,336    93.9%
Income tax benefit   (10)   8,859    (8,869)   (100.0%)
Net loss  $(5,590)  $(82,057)  $76,467    93.2%

 

Research and development expenses

 

Research and development expenses were approximately $1.2 million for the six months ended June 30, 2024, a decrease of approximately $1.1 million or 46.3% from the six months ended June 30, 2023. The decrease is primarily attributable to a decrease of $0.8 million in the manufacturing and pre-clinical costs of IC 100 and a decrease of approximately $0.5 million in payroll expenses due to employee attrition. This was slightly offset by an increase of approximately $0.3 million in CRO expenses for the production of VAR 200.

 

General and administrative expenses

 

General and administrative expenses were approximately $4.4 million for the six months ended June 30, 2024, a decrease of approximately $3.1 million or 41.6% from the six months ended June 30, 2023. The decrease is primarily attributable to $1.2 million of common stock granted to certain members of the Sponsor and recognized in 2023 in exchange for increasing the duration of the period during which they are not permitted to sell their common stock, a $0.5 million decrease in professional fees due to reduced fees related to changes in public auditors and legal counsel, a $0.2 million decrease in marketing costs for investor and public relations as a result of a reduction in marketing vendors in 2024, and $0.4 million decrease in payments for the Effectiveness Failure related to shares issued to investors pursuant to a securities purchase agreement in July 2022, a $0.3 million decrease in director and officer insurance due to reduced costs in the second year of being a public company, and $0.5 million decrease in payroll expenses as a result of a bonus accrual recognized upon board approval.

 

Impairment of In-Process Research and Development and Goodwill

 

For the six months ended June 30, 2023, impairment of in-process research and development and impairment of goodwill were $69.3 million and $11.9 million, respectively. The impairment was a result of the decline in stock value and market capitalization of the Company at June 30, 2023. There was no impairment for the six months ended June 30, 2024.

 

18
 

 

Cash Flows

 

The following table summarizes our cash flows from operating and financing activities for the six months ended June 30, 2024 and for the six months ended June 30, 2023:

 

   For the Six Months Ended June 30,   Increase 
(in thousands)  2024   2023   (decrease) 
Net cash provided by (used in)               
Operating activities  $(5,691)  $(4,997)  $(694)
Financing activities   2,673    (677)   3,350 
Net Decrease in Cash  $(3,018)  $(5,674)  $2,656 

 

Cash Flows from Operating Activities

 

Net cash used in operating activities was approximately $5.7 million and approximately $5.0 million for the six months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and for the six months ended June 30, 2023, the net cash used in operating activities was primarily attributable to the net loss of approximately $5.6 million and $82.1 million, respectively, offset by $0.5 million and $74.8 million, respectively, of net non-cash expenses, and approximately ($0.6) million and $2.3 million, respectively, of cash (used in) generated by the levels of operating assets and liabilities, respectively.

 

Net Cash Provided By (Used In) Financing Activities

 

Net cash provided by (used in) financing activities was $2.7 million and ($0.7) million for the six months ended June 30, 2024 and 2023, respectively. Cash provided by financing activities during the six months ended June 30, 2024 represented proceeds from the exercise of warrants. Cash used in financing activities during the six months ended June 30, 2023 primarily represented $10.5 million in cash paid for the redemption of Series A Preferred Stock and $1.2 million in registration and issuance costs associated with common stock issuances. This was partially offset by $11.0 million in proceeds from the issuance of common stock in a public offering.

 

Liquidity and Capital Resources

 

The following table summarizes our total current assets, liabilities and working capital deficiency at June 30, 2024 and 2023, respectively:

 

   June 30,   December 31, 
(in thousands)  2024   2023 
Current Assets  $641   $3,353 
Current Liabilities  $9,995   $10,195 
Working Capital Deficiency  $(9,354)  $(6,842)

 

Since our inception in 2014 through June 30, 2024, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations. Based on our current operating plan, we expect our cash of $0.1 million as of June 30, 2024 will only be sufficient to fund our operating expenses and capital expenditure requirements on a month-to-month basis. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.

 

19
 

 

Going Concern

 

Since inception we have been engaged in organizational activities, including raising capital and research and development activities. We have not generated revenues and have not yet achieved profitable operations, nor have we ever generated positive cash flow from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. We are subject to those risks associated with any pre-revenue stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and are largely dependent on the services of our employees and consultants. Further, our future operations are dependent on the success of our efforts to raise additional capital. These uncertainties raise substantial doubt about our ability to continue as a going concern for 12 months after the issuance date of our financial statements. The accompanying financial statements have been prepared on a going concern basis. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of us to continue as a going concern, which contemplates the continuation of operations, realization of assets and liquidation of liabilities in the ordinary course of business. We incurred a net loss of $5.6 million for the six months ended June 30, 2024 and a net loss of $82.1 million for the six months ended June 30, 2023, and we had an accumulated deficit of $108.8 million at June 30, 2024. We anticipate incurring additional losses until such time, if ever, that we can generate significant revenue from our product candidates currently in development. Our primary source of capital has been the issuance of debt and equity securities. We believe that current cash is only sufficient to fund operations and capital requirements on a month-to-month basis. Additional financing will be needed by us to fund our operations, to complete development of and to commercially develop our product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

 

Contractual Obligations

 

The following summarizes our contractual obligations as of June 30, 2024 that will affect our future liquidity. Based on our current operating plan, we plan to satisfy the obligations identified below from our current cash balance and future financing.

 

Cash requirements for our current liabilities as of June 30, 2024 include approximately $10.0 million for accounts payable and accrued expenses.

 

Capital Needs

 

We intend to raise additional capital in the future to fund continued development of VAR200 and IC100.

 

We expect to raise additional capital by issuing equity, equity-linked securities, or debt in subsequent offerings. If we are unable to raise additional capital on terms favorable to us, we may not have sufficient liquidity to execute on our business strategy. We have various warrants outstanding that can be exercised for our common stock, many of which must be exercised in exchange for cash paid to us by the holders of such warrants. If the market price of our common stock is less than the exercise price of a holder’s warrants, it is unlikely that holders will exercise their warrants. As such, we do not expect to receive significant proceeds in the near term from the exercise of most of our warrants based on the current market price of our common stock and the exercise prices of such warrants.

 

Our policy is to invest any cash in excess of our immediate requirements in investments designed to preserve the principal balance and provide liquidity while producing a modest return on investment. Accordingly, our cash equivalents will be invested primarily in money market funds.

 

20
 

 

We expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced manufacturing expenses. In addition, we expect to incur additional expenses to add operational, financial and information systems and personnel, including personnel to support our planned product commercialization efforts. We also expect to incur significant costs to comply with corporate governance, internal controls and similar requirements applicable to us as a public company.

 

Our future use of operating cash and capital requirements will depend on many forward-looking factors, including the following:

 

  ● the initiation, progress, timing, costs and results of clinical trials for our product candidates;
  ● the clinical development plans we establish for each product candidate;
  ● the number and characteristics of product candidates that we develop or may in-license;
  ● the terms of any collaboration agreements we may choose to execute;
  ● the outcome, timing and cost of meeting regulatory requirements established by the FDA or other comparable foreign regulatory authorities;
  ● the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
  ● the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;
  ● the cost and timing of the implementation of commercial scale manufacturing activities; and
  ● the cost of establishing, or outsourcing, sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.

 

To continue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trials of our product candidates, and other operations and potential product acquisitions and in-licensing. We have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in-license and develop additional products and product candidates to augment our internal development pipeline. Strategic transaction opportunities that we may pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. In addition, we may pursue development, acquisition or in-licensing of approved or development products in new or existing therapeutic areas or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes. Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or could be structured as a collaboration or partnering arrangement. We have no arrangements, agreements, or understandings in place at the present time to enter into any acquisition, in-licensing or similar strategic business transaction. In addition, we continue to evaluate commercial collaborations and strategic relationships with established pharmaceutical companies, which would provide us with more immediate access to marketing, sales, market access and distribution infrastructure.

 

21
 

 

If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences that are not favorable to us or our existing stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.

 

JOBS Act Accounting Election

 

ZyVersa is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. The JOBS Act permits companies with emerging growth company status to take advantage of an extended transition period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. ZyVersa expects to use this extended transition period to enable it to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date the Company (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company effective dates.

 

In addition, the Company intends to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

Critical Accounting Estimates

 

We prepare our condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

 

We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statements that require estimation but are not deemed critical, as defined above.

 

22
 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer (who serve as our Principal Executive Officer and Principal Financial and Accounting Officer, respectively), to allow timely decisions regarding required disclosure.

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2024. Based upon their evaluation and due to the material weakness cited below, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were ineffective.

 

Specifically, management’s conclusion was based on the following material weakness which existed as of December 31, 2023 and June 30, 2024:

 

  ● Business process controls across the entity’s financial reporting processes were not effectively designed and implemented to properly address the risk of material misstatement, including controls without proper segregation of duties between preparer and reviewer

 

Our management is committed to taking further action and implementing necessary enhancements or improvements, including actions to address the material weakness identified as of December 31, 2023. Management expects to complete the development and implementation of its remediation plan during 2024.

 

Changes in Internal Control over Financial Reporting

 

During the most recent fiscal quarter, management has implemented additional controls to address the material weakness identified as of December 31, 2023. This includes the implementation of proper segregation of duties controls between preparer and reviewer. However, the material weakness will not be deemed to be remediated until the controls have been operational for a period of time and have been verified to be operating effectively.

 

Inherent Limitations of the Effectiveness of Controls

 

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. A control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

 

23
 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

None.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company”, we are not required to provide information required by this Item. However, investors are encouraged to review our current risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 25, 2024, as amended on May 15, 2024.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

Insider Trading Plans

 

During the six months ended June 30, 2024, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 

 

24
 

 

ITEM 6. EXHIBITS.

 

Exhibit   Description
3.1*   Seconded Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc., as amended.
4.1  

Form of Series A-1 Warrant (incorporated by reference to Exhibit 4.1 of the Company’s current report on Form 8-K filed with the SEC on August 1, 2024).

4.2  

Form of Series B-1 Warrant (incorporated by reference to Exhibit 4.2 of the Company’s current report on Form 8-K filed with the SEC on August 1, 2024).

10.1  

Inducement Letter, dated August 1, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on August 1, 2024).

10.2  

Financial Advisory Agreement, dated August 1, 2024 (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed with the SEC on August 1, 2024).

31.1*   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
31.2*   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
101.INS**   XBRL Inline Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101).

 

* Filed herewith.
** Furnished herewith.

 

25
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 9, 2024 By: /s/ Stephen C, Glover
    Stephen C. Glover
    Chief Executive Officer
    (Principal Executive Officer)
     
Dated: August 9, 2024 By: /s/ Peter Wolfe
    Peter Wolfe
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

26

 

 

Exhibit 3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 31.1

 

Certification of

Principal Executive Officer

of ZyVersa Therapeutics, Inc.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Stephen C. Glover, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of ZyVersa Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
   
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 9, 2024 By: /s/ Stephen C. Glover
    Stephen C. Glover
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 

Exhibit 31.2

 

Certification of

Principal Executive Officer

of ZyVersa Therapeutics, Inc.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Peter Wolfe, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of ZyVersa Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
   
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 9, 2024 By: /s/ Peter Wolfe
    Peter Wolfe
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of ZyVersa Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

Dated: August 9, 2024 By: /s/ Stephen C. Glover
    Stephen C. Glover
    Chief Executive Officer
    (Principal Executive Officer)

 

Dated: August 9, 2024 By: /s/ Peter Wolfe
    Peter Wolfe
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

v3.24.2.u1
Cover - $ / shares
 6 Months Ended
Jun. 30, 2024
Aug. 08, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2024  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41184  
Entity Registrant Name ZYVERSA THERAPEUTICS, INC.  
Entity Central Index Key 0001859007  
Entity Tax Identification Number 86-2685744  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 2200 N. Commerce Parkway  
Entity Address, Address Line Two Suite 208  
Entity Address, City or Town Weston  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33326  
City Area Code (754)  
Local Phone Number 231-1688  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol ZVSA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,029,196
Entity Listing, Par Value Per Share $ 0.0001  
v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current Assets:    
Cash $ 119,486 $ 3,137,674
Prepaid expenses and other current assets 521,906 215,459
Total Current Assets 641,392 3,353,133
Equipment, net 1,733 6,933
In-process research and development 18,647,903 18,647,903
Vendor deposit 178,476 98,476
Operating lease right-of-use asset 7,839
Total Assets 19,469,504 22,114,284
Current Liabilities:    
Accounts payable 8,316,506 8,431,583
Accrued expenses and other current liabilities 1,678,322 1,754,533
Operating lease liability 8,656
Total Current Liabilities 9,994,828 10,194,772
Deferred tax liability 854,621 844,914
Total Liabilities 10,849,449 11,039,686
Commitments and contingencies (Note 6)
Stockholders’ Equity:    
Common stock value 83 40
Additional paid-in-capital 117,436,743 114,300,849
Accumulated deficit (108,809,604) (103,219,124)
Treasury stock, at cost, 7 shares at June 30, 2024 and December 31, 2023, respectively (7,168) (7,168)
Total Stockholders’ Equity 8,620,055 11,074,598
Total Liabilities and Stockholders’ Equity 19,469,504 22,114,284
Series A Preferred Stock [Member]    
Stockholders’ Equity:    
Preferred stock value
Series B Preferred Stock [Member]    
Stockholders’ Equity:    
Preferred stock value $ 1 $ 1
v3.24.2.u1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 834,903 405,212
Common stock, shares outstanding 834,896 402,205
Treasury stock shares 7 7
Series A Preferred Stock [Member]    
Preferred stock, shares authorized 8,635 8,635
Preferred stock, shares issued 50 50
Preferred stock, shares outstanding 50 50
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 5,062 5,062
Preferred stock, shares issued 5,062 5,062
Preferred stock, shares outstanding 5,062 5,062
v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating Expenses:        
Research and development $ 709,049 $ 1,220,576 $ 1,221,987 $ 2,276,519
General and administrative 2,044,929 3,929,225 4,358,627 7,465,362
Impairment of in-process research and development 69,280,171 69,280,171
Impairment of goodwill 11,895,033 11,895,033
Total Operating Expenses 2,753,978 86,325,005 5,580,614 90,917,085
Loss From Operations (2,753,978) (86,325,005) (5,580,614) (90,917,085)
Other (Income) Expense:        
Interest (income) expense 58 314 159 (765)
Pre-Tax Net Loss (2,754,036) (86,325,319) (5,580,773) (90,916,320)
Income tax (provision) benefit (9,707) 7,812,226 (9,707) 8,859,277
Net Loss (2,763,743) (78,513,093) (5,590,480) (82,057,043)
Deemed dividend to preferred stockholders (7,915,836) (7,915,836)
Net Loss Attributable to Common Stockholders $ (2,763,743) $ (86,428,929) $ (5,590,480) $ (89,972,879)
Net Loss Per Share        
Net loss per share, basic $ (3.31) $ (1,694.12) $ (7.67) $ (2,329.76)
Net loss per share, diluted $ (3.31) $ (1,694.12) $ (7.67) $ (2,329.76)
Weighted Average Number of Common Shares Outstanding        
Weighted average number of shares outstanding, basic 834,915 51,017 729,306 38,619
Weighted average number of shares outstanding, diluted 834,915 51,017 729,306 38,619
v3.24.2.u1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Treasury Stock, Common [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2022 $ 1 $ 1 $ 3 $ 104,584,170 $ (4,921,178) $ 99,662,997
Balance, shares at Dec. 31, 2022 8,635 5,062 25,760      
Issuance of common stock pursuant to vendor agreements 395,200 395,200
Issuance of common stock pursuant to vendor agreements, shares     371        
Stock-based compensation 287,461 287,461
Net loss (3,543,950) (3,543,950)
Reclassification of formerly redeemable common stock 331,331 331,331
Reclassification of formerly redeemable common stock, shares     188        
Registration costs associated with preferred stock issuance (34,674) (34,674)
Balance at Mar. 31, 2023 $ 1 $ 1 $ 3 105,563,488 (8,465,128) 97,098,365
Balance, shares at Mar. 31, 2023 8,635 5,062 26,319      
Balance at Dec. 31, 2022 $ 1 $ 1 $ 3 104,584,170 (4,921,178) 99,662,997
Balance, shares at Dec. 31, 2022 8,635 5,062 25,760      
Net loss             (82,057,043)
Balance at Jun. 30, 2023 $ 1 $ 7 $ (7,168) 107,047,023 (86,978,221) 20,061,642
Balance, shares at Jun. 30, 2023 200 5,062 67,626 (7)      
Balance at Mar. 31, 2023 $ 1 $ 1 $ 3 105,563,488 (8,465,128) 97,098,365
Balance, shares at Mar. 31, 2023 8,635 5,062 26,319      
Issuance of common stock pursuant to vendor agreements 210,000 210,000
Issuance of common stock pursuant to vendor agreements, shares     1,086        
Stock-based compensation 365,742 365,742
Net loss (78,513,093) (78,513,093)
Registered offering of common stock [1] $ 3 9,831,016 9,831,019
Registered offering of common stock , shares     31,473        
Redemption of Series A Preferred Stock $ (1) (10,080,000) (10,080,001)
Redemption of Series A Preferred Stock, shares (8,400)            
Conversion of Series A Preferred Stock into common stock
Conversion of series A preferred stock into common stock , shares (35)   50        
Shares issued as consideration for extension of lock-up period $ 1 1,156,777 1,156,778
Shares issued as consideration for extension of lock-up period, shares     8,698        
Treasury stock acquired, at cost $ (7,168) (7,168)
Treasury stock acquired, at cost, shares       (7)      
Balance at Jun. 30, 2023 $ 1 $ 7 $ (7,168) 107,047,023 (86,978,221) 20,061,642
Balance, shares at Jun. 30, 2023 200 5,062 67,626 (7)      
Balance at Dec. 31, 2023 $ 1 $ 40 $ (7,168) 114,300,849 (103,219,124) 11,074,598
Balance, shares at Dec. 31, 2023 50 5,062 405,212 (7)      
Exercise of warrants $ 21 2,672,479 2,672,500
Exercise of warrants, shares     213,800        
Exercise of pre-funded warrants $ 13 (13)
Exercise of pre-funded warrants, shares     131,481        
Issuance of common stock pursuant to vendor agreements $ 1 79,199 79,200
Issuance of common stock pursuant to vendor agreements, shares     9,000        
Round up share adjustment due to reverse split $ 8 (8)
Round up share adjustment due to reverse split, shares     75,410        
Stock-based compensation 223,573 223,573
Net loss (2,826,737) (2,826,737)
Balance at Mar. 31, 2024 $ 1 $ 83 $ (7,168) 117,276,079 (106,045,861) 11,223,134
Balance, shares at Mar. 31, 2024 50 5,062 834,903 (7)      
Balance at Dec. 31, 2023 $ 1 $ 40 $ (7,168) 114,300,849 (103,219,124) 11,074,598
Balance, shares at Dec. 31, 2023 50 5,062 405,212 (7)      
Net loss             (5,590,480)
Balance at Jun. 30, 2024 $ 1 $ 83 $ (7,168) 117,436,743 (108,809,604) 8,620,055
Balance, shares at Jun. 30, 2024 50 5,062 834,903 (7)      
Balance at Mar. 31, 2024 $ 1 $ 83 $ (7,168) 117,276,079 (106,045,861) 11,223,134
Balance, shares at Mar. 31, 2024 50 5,062 834,903 (7)      
Stock-based compensation 160,664 160,664
Net loss (2,763,743) (2,763,743)
Balance at Jun. 30, 2024 $ 1 $ 83 $ (7,168) $ 117,436,743 $ (108,809,604) $ 8,620,055
Balance, shares at Jun. 30, 2024 50 5,062 834,903 (7)      
v3.24.2.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash Flows From Operating Activities:    
Net loss $ (5,590,480) $ (82,057,043)
Adjustments to reconcile net loss to net cash used in operating activities:    
Impairment of in-process research and development 69,280,171
Impairment of goodwill 11,895,033
Stock-based compensation 384,237 653,203
Issuance of common stock pursuant to vendor agreements 79,200 605,200
Shares issued as consideration for extension of lock-up period 1,156,778
Depreciation of fixed assets 5,200 5,200
Non-cash rent expense 7,839 44,473
Deferred tax provision (benefit) 9,707 (8,882,516)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (306,447) (661,564)
Security deposit 46,659
Vendor deposits (80,000) 235,000
Accounts payable (115,077) 2,118,388
Operating lease liability (8,656) (49,131)
Accrued expenses and other current liabilities (76,211) 613,077
Net Cash Used In Operating Activities (5,690,688) (4,997,072)
Cash Flows From Financing Activities:    
Proceeds from issuance of common stock in public offering 11,015,500
Registration and issuance costs associated with common stock issuance (1,213,657)
Redemption of Series A Preferred Stock (10,465,610)
Exercise of warrants 2,672,500
Purchase of treasury stock (7,168)
Registration and issuance costs associated with preferred stock issuance (5,500)
Net Cash Provided By (Used In) Financing Activities 2,672,500 (676,435)
Net Decrease in Cash (3,018,188) (5,673,506)
Cash - Beginning of Period 3,137,674 5,902,199
Cash - End of Period 119,486 228,693
Supplemental Disclosures of Cash Flow Information:    
Reclassification of formerly redeemable common stock 331,331
Accounts payable for deferred offering costs $ 44,892
v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure [Table]            
Net Income (Loss) $ (2,763,743) $ (2,826,737) $ (78,513,093) $ (3,543,950) $ (5,590,480) $ (82,057,043)
v3.24.2.u1
Insider Trading Arrangements
 6 Months Ended
Jun. 30, 2024
Insider Trading Arrangements [Line Items]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.2.u1
Business Organization, Nature of Operations and Basis of Presentation
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization, Nature of Operations and Basis of Presentation

Note 1 – Business Organization, Nature of Operations and Basis of Presentation

 

Organization and Operations

 

ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024 and as amended on May 15, 2024.

 

On December 4, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2023 Reverse Split.

 

On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split.

 

Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2023 Reverse Split and the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented. See Note 7 – Stockholders’ Permanent and Temporary Equity – Reverse Stock Split.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 
v3.24.2.u1
Going Concern and Management’s Plans
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern and Management’s Plans

Note 2 - Going Concern and Management’s Plans

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

As of June 30, 2024, the Company had cash of approximately $0.1 million and a working capital deficit of approximately $9.3 million. During the six months ended June 30, 2024, the Company incurred a net loss of approximately $5.6 million and used cash in operations of approximately $5.7 million. The Company has an accumulated deficit of approximately $108.8 million as of June 30, 2024.

 

The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

 

Consequently, the Company will be required to raise additional funds through equity or debt financing. On August 1, 2024, the Company received approximately $0.8 million upon the exercise of warrants. See Note 8 – Subsequent Events – Stock Warrants for additional details. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

 
v3.24.2.u1
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

 

Since the date the Company’s December 31, 2023 financial statements were issued in its 2023 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies.

 

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Net Loss Per Common Share

 

Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period.

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

  

   2024   2023 
   As of June 30, 
   2024   2023 
Warrants [1]   689,293    67,835 
Options   9,671    10,243 
Series A Convertible Preferred Stock   72    286 
Series B Convertible Preferred Stock   2,067    2,067 
Total potentially dilutive shares   701,103    80,431 

 

[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.

 

Segment Reporting

 

The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

 

Reclassifications

 

Certain prior period balances have been reclassified from security deposits to vendor deposits on the condensed consolidated balance sheet in order to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 
v3.24.2.u1
Accrued Expenses and Other Current Liabilities
 6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities

Note 4 – Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following as of June 30, 2024 and December 31, 2023:

  

   June 30,   December 31, 
   2024   2023 
         
L&F milestone payment liability  $-   $500,000 
Payroll accrual   731,717    668,803 
Other accrued expenses   21,969    41,969 
Bonus accrual   917,375    536,500 
Registration delay liability [1]   7,261    7,261 
Total accrued expenses and other current liabilities  $1,678,322   $1,754,533 

 

[1]See Note 7 - Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

 
v3.24.2.u1
Income Taxes
 6 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes

Note 5 – Income Taxes

 

Income tax expense and the effective tax rate were as follows:

  

(in thousands)  2024   2023 
   For the Six Months Ended 
   June 30, 
(in thousands)  2024   2023 
         
Income tax (expense) benefit  $(9,707)  $8,859,277 
           
Effective tax rate   (0.17)%   9.70%

 

The tax provisions for the six months ended June 30, 2024 and 2023 were computed using the estimated effective tax rates applicable to the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision, as necessary. The Company’s effective tax rate was (0.17)% and 9.7% for the six months ended June 30, 2024 and 2023. The decrease in the quarterly rates is primarily the result of the Company recording a full valuation allowance during the six months ended June 30, 2024 due to the reversal of a significant deferred tax liability that existed as of June 30, 2023.

 
v3.24.2.u1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6 – Commitments and Contingencies

 

Litigations, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

Disputed Vendor Invoices

 

On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice consisted of miscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing these invoices and has requested the vendor to rescind each of them. Given that the invoices are being disputed, the Company has not accrued for these invoices as of June 30, 2024.

 

License Agreements

 

L&F Research LLC

 

The Company entered into a License Agreement with L&F Research LLC (“L&F Research”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis.

 

On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). Waiver A was contingent upon (i) forgiveness by the Company of $351,579 in aggregate principal amount outstanding under a certain convertible note, and (ii) a cash payment by the Company to L&F in the amount of $648,421, on or before March 31, 2023. Waiver B was contingent upon a cash payment by the Company to L&F in the amount of $500,000 on or before the earlier of (x) January 31, 2024, and (y) ten business days from the date that the Company received net proceeds of at least $30,000,000 from the issuance of new equity capital. All other terms of the L&F License remain in effect.

 

On March 29, 2023, the Company paid the $648,421 of cash to L&F, thus meeting the conditions of Waiver A, which also had the effect of canceling the Note Receivable and the Put Option and resulted in a reclassification of 188 shares of common stock and $331,331 classified as temporary equity to permanent equity.

 

On January 30, 2024, the Company paid $500,000 of cash to L&F, thus meeting the conditions of Waiver B.

 

Operating Leases

 

On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and increases approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months.

 

The Company recognized right-of-use asset amortization of $0 and $7,839 in connection with its operating lease for the three and six months ending June 30, 2024 and the Company recognized rent expense of $43,271 and $84,743 in connection with its operating lease for the three and six months ending June 30, 2024.

 

The Company recognized right-of-use amortization of $38,783 and $77,198 in connection with its operating lease for the three and six months ending June 30, 2023, respectively.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

A summary of the Company’s right-of-use assets and liabilities is as follows:

  

   2024   2023 
   For the Six Months Ended 
   June 30, 
   2024   2023 
         
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows used in operating activities  $8,656   $49,130 
           
Right-of-use assets obtained in exchange for lease obligations          
Operating leases  $-   $- 
           
Weighted Average Remaining Lease Term          
Operating leases   -    0.59 Years 
           
Weighted Average Discount Rate          
Operating leases   -    6.5%

 
v3.24.2.u1
Stockholders’ Permanent and Temporary Equity
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
Stockholders’ Permanent and Temporary Equity

Note 7 – Stockholders’ Permanent and Temporary Equity

 

Reverse Stock Split

 

On April 25, 2024, the Company effected the 2024 Reverse Split. Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split. See Note 1 – Business Organization, Nature of Operations and Basis of Presentation for additional details.

 

Common Stock

 

During the six months ended June 30, 2024, the Company entered into a marketing agreement with a vendor in which the Company issued an aggregate of 9,000 shares of common stock and cash in exchange for marketing services. The $79,200 fair value of the common stock was established as a prepaid expense and the Company will recognize the expense over the terms of the contracts.

 

Temporary Equity

 

See Note 6 – Commitments and Contingencies for discussion of the movement of temporary equity to permanent equity on March 29, 2023.

 

Stock-Based Compensation

 

For the three months ended June 30, 2024 the Company recorded stock-based compensation expense of $160,664 (of which, $15,447 was included in research and development and $145,217 was included in general and administrative expense) related to options issued to employees and consultants. For the three months ended June 30, 2023 the Company recorded stock-based compensation expense of $365,742 (of which, $109,066 was included in research and development and $256,676 was included in general and administrative expense) related to options issued to employees and consultants.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

For the six months ended June 30, 2024 the Company recorded stock-based compensation expense of $384,237 (of which, $30,895 was included in research and development and $353,342 was included in general and administrative expense) related to options issued to employees and consultants. For the six months ended June 30, 2023 the Company recorded stock-based compensation expense of $653,203 (of which, $158,521 was included in research and development and $494,682 was included in general and administrative expense) related to options issued to employees and consultants. As of June 30, 2024 there was $643,224 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.4 years.

 

Stock Options

 

The grant date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:

  

   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
Fair value of common stock on date of grant  N/A   $0.44   N/A   $0.44 - $2.23 
Risk free interest rate  N/A    3.76%  N/A    3.53% - 4.27%
Expected term (years)  N/A    6.00   N/A    6.00 
Expected volatility  N/A    122%  N/A    120% - 123%
Expected dividends  N/A    0.00%  N/A    0.00%

 

A summary of the option activity for the six months ended June 30, 2024 is presented below:

  

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
                 
Outstanding, January 1, 2024   10,243   $2,218.51                  
Granted   -    -           
Exercised   -    -           
Expired   (572)   1,760.50           
Outstanding, June 30, 2024   9,671   $2,245.60    5.8   $- 
                     
Exercisable, June 30, 2024   6,823   $2,979.56    5.9   $- 

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

The following table presents information related to stock options as of June 30, 2024:

  

Options Outstanding    Options Exercisable 
           Weighted      
      Outstanding    Average    Exercisable 
Exercise    Number of    Remaining Life    Number of 
Price    Options    In Years    Options 
$152.50    4,157    8.9    1,674 
$738.50    286    8.6    95 
$791.00    38    8.7    12 
$1,760.50    1,338    2.3    1,338 
$3,965.50    37    8.0    37 
$4,053.00    2,095    4.8    2,095 
$5,726.00    1,720    6.9    1,572 
      9,671    5.9    6,823 

 

Stock Warrants

 

Between February 26, 2024 and March 6, 2024, investors in the December 2023 Offering exercised warrants to purchase 213,800 shares of common stock at an exercise price of $12.50 per share for total proceeds of $2,672,500.

 

Between January 17 and February 23, 2024, a December 2023 Offering investor exercised pre-funded warrants to purchase 131,500 shares of common stock on a cashless basis to purchase 131,481 shares of common stock at an exercise price of $0.001 per share.

 

A summary of the warrant activity for the six months ended June 30, 2024, is presented below:

  

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Warrants   Price   In Years   Value 
                 
Outstanding, January 1, 2024 [1]   903,320   $123.44                     
Issued   -    -           
Forfeited   (227)   4,053.00           
Exercised [2]   (213,800)   12.50           
Outstanding, June 30, 2024   689,293   $156.64    3.42   $- 
                     
Exercisable, June 30, 2024   689,093   $156.17    3.42   $- 

 

[1]Warrants outstanding exclude 131,500 December 2023 Pre-Funded Warrants outstanding with an exercise price of $0.001.

 

[2]Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 

The following table presents information related to stock warrants as of June 30, 2024:

  

Warrants Outstanding    Warrants Exercisable 
      Outstanding    Weighted Average    Exercisable  
Exercise    Number of    Remaining Life    Number of 
Price    Warrants    In Years    Warrants 
$12.50    586,200    3.33    586,200 
$47.50    20,347    4.70    20,347 
$57.75    19,965    4.02    19,965 
$350.00    27,551    3.83    27,551 
$700.00    13,944    3.45    13,944 
$1,760.50    300    0.19    100 
$2,415.00    3,651    3.45    3,651 
$4,025.00    17,335    3.45    17,335 
      689,293    3.42    689,093 

 

Effectiveness Failure

 

In connection with the business combination with Larkspur Health Acquisition Corp., the Company conducted the Series A Preferred Stock Financing. On or about February 20, 2023, the Company failed to have the SEC declare a registration statement effective (the “Effectiveness Failure”) which covered the Series A Preferred Stock registrable securities within the time period prescribed by the Securities Purchase Agreement (the “SPA”). The SPA entitles the investors to receive registration delay payments (“Registration Delay Payments”) equal to 1.5% of each investor’s purchase price on the date of the Effectiveness Failure and every thirty days thereafter that the Effectiveness Failure persists. Failure to make the Registration Delay Payments on a timely basis result in the accrual of interest at the rate of 2.0% per month. On April 28, 2023, the proceeds from the April 2023 Offering were used to make most of the Registration Delay Payments and redeem substantially all of the Series A Preferred Stock. As of June 30, 2024, the Company has accrued additional Registration Delay Payments of approximately $7,261 in the aggregate.

 
v3.24.2.u1
Subsequent Events
 6 Months Ended
Jun. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events

Note 8 – Subsequent Events

 

Stock Warrants

 

On August 1, 2024, the Company initiated a limited time program, which was immediately accepted by the warrant holder, that permitted the holder to exercise its December 2023 Offering warrants at a reduced exercise price of $3.46 per share and granted new warrants to purchase (i) 392,000 shares of common stock with an exercise term of 5 years from stockholder approval and (ii) 86,600 shares of common stock with an exercise term of 18 months from stockholder approval. Both warrants have an exercise price of $3.46 per share. Under the program, the warrant holder submitted an exercise notice and the related aggregate cash exercise price to purchase 239,300 shares of common stock on August 1, 2024 for gross proceeds of $827,978. However, due to beneficial ownership limitations, only 194,300 of the 239,300 shares of common stock have been issued through the filing date. The remaining 45,000 unissued shares of common stock and the related exercise proceeds are held in abeyance pending availability under the beneficial ownership limitations. Issuance costs include financial advisor fees of $50,000 and reimbursement to the financial advisor for legal expenses.
v3.24.2.u1
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

 

 

ZYVERSA THERAPEUTICS, INC.

 

Notes to Condensed Consolidated Financial Statements

 
Net Loss Per Common Share

Net Loss Per Common Share

 

Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period.

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

  

   2024   2023 
   As of June 30, 
   2024   2023 
Warrants [1]   689,293    67,835 
Options   9,671    10,243 
Series A Convertible Preferred Stock   72    286 
Series B Convertible Preferred Stock   2,067    2,067 
Total potentially dilutive shares   701,103    80,431 

 

[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.

 
Segment Reporting

Segment Reporting

 

The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

 
Reclassifications

Reclassifications

 

Certain prior period balances have been reclassified from security deposits to vendor deposits on the condensed consolidated balance sheet in order to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.
v3.24.2.u1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

  

   2024   2023 
   As of June 30, 
   2024   2023 
Warrants [1]   689,293    67,835 
Options   9,671    10,243 
Series A Convertible Preferred Stock   72    286 
Series B Convertible Preferred Stock   2,067    2,067 
Total potentially dilutive shares   701,103    80,431 

 

[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.
v3.24.2.u1
Accrued Expenses and Other Current Liabilities (Tables)
 6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of June 30, 2024 and December 31, 2023:

  

   June 30,   December 31, 
   2024   2023 
         
L&F milestone payment liability  $-   $500,000 
Payroll accrual   731,717    668,803 
Other accrued expenses   21,969    41,969 
Bonus accrual   917,375    536,500 
Registration delay liability [1]   7,261    7,261 
Total accrued expenses and other current liabilities  $1,678,322   $1,754,533 

 

[1]See Note 7 - Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.
v3.24.2.u1
Income Taxes (Tables)
 6 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income Taxes Expense Effective Tax Rate

Income tax expense and the effective tax rate were as follows:

  

(in thousands)  2024   2023 
   For the Six Months Ended 
   June 30, 
(in thousands)  2024   2023 
         
Income tax (expense) benefit  $(9,707)  $8,859,277 
           
Effective tax rate   (0.17)%   9.70%
v3.24.2.u1
Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Right of Use Assets and Liabilities

A summary of the Company’s right-of-use assets and liabilities is as follows:

  

   2024   2023 
   For the Six Months Ended 
   June 30, 
   2024   2023 
         
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows used in operating activities  $8,656   $49,130 
           
Right-of-use assets obtained in exchange for lease obligations          
Operating leases  $-   $- 
           
Weighted Average Remaining Lease Term          
Operating leases   -    0.59 Years 
           
Weighted Average Discount Rate          
Operating leases   -    6.5%
v3.24.2.u1
Stockholders’ Permanent and Temporary Equity (Tables)
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
Schedule of Stock Options Granted

The grant date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:

  

   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
Fair value of common stock on date of grant  N/A   $0.44   N/A   $0.44 - $2.23 
Risk free interest rate  N/A    3.76%  N/A    3.53% - 4.27%
Expected term (years)  N/A    6.00   N/A    6.00 
Expected volatility  N/A    122%  N/A    120% - 123%
Expected dividends  N/A    0.00%  N/A    0.00%
Schedule of Stock Option Activity

A summary of the option activity for the six months ended June 30, 2024 is presented below:

  

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
                 
Outstanding, January 1, 2024   10,243   $2,218.51                  
Granted   -    -           
Exercised   -    -           
Expired   (572)   1,760.50           
Outstanding, June 30, 2024   9,671   $2,245.60    5.8   $- 
                     
Exercisable, June 30, 2024   6,823   $2,979.56    5.9   $- 
Schedule of Information Related to Stock Options

The following table presents information related to stock options as of June 30, 2024:

  

Options Outstanding    Options Exercisable 
           Weighted      
      Outstanding    Average    Exercisable 
Exercise    Number of    Remaining Life    Number of 
Price    Options    In Years    Options 
$152.50    4,157    8.9    1,674 
$738.50    286    8.6    95 
$791.00    38    8.7    12 
$1,760.50    1,338    2.3    1,338 
$3,965.50    37    8.0    37 
$4,053.00    2,095    4.8    2,095 
$5,726.00    1,720    6.9    1,572 
      9,671    5.9    6,823 
Summary of Warrant Activity

A summary of the warrant activity for the six months ended June 30, 2024, is presented below:

  

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Warrants   Price   In Years   Value 
                 
Outstanding, January 1, 2024 [1]   903,320   $123.44                     
Issued   -    -           
Forfeited   (227)   4,053.00           
Exercised [2]   (213,800)   12.50           
Outstanding, June 30, 2024   689,293   $156.64    3.42   $- 
                     
Exercisable, June 30, 2024   689,093   $156.17    3.42   $- 

 

[1]Warrants outstanding exclude 131,500 December 2023 Pre-Funded Warrants outstanding with an exercise price of $0.001.

 

[2]Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.
Schedule of Information Related to Stock Warrants

The following table presents information related to stock warrants as of June 30, 2024:

  

Warrants Outstanding    Warrants Exercisable 
      Outstanding    Weighted Average    Exercisable  
Exercise    Number of    Remaining Life    Number of 
Price    Warrants    In Years    Warrants 
$12.50    586,200    3.33    586,200 
$47.50    20,347    4.70    20,347 
$57.75    19,965    4.02    19,965 
$350.00    27,551    3.83    27,551 
$700.00    13,944    3.45    13,944 
$1,760.50    300    0.19    100 
$2,415.00    3,651    3.45    3,651 
$4,025.00    17,335    3.45    17,335 
      689,293    3.42    689,093 
v3.24.2.u1
Business Organization, Nature of Operations and Basis of Presentation (Details Narrative)
Apr. 25, 2024
Dec. 04, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Reverse stock split the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
v3.24.2.u1
Going Concern and Management’s Plans (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Aug. 01, 2024
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Subsequent Event [Line Items]                
Cash   $ 119,486       $ 119,486   $ 3,137,674
Working capital deficit   9,300,000       9,300,000    
Net loss   2,763,743 $ 2,826,737 $ 78,513,093 $ 3,543,950 5,590,480 $ 82,057,043  
Net cash used In operating activities           (5,690,688) (4,997,072)  
Accumulated deficit   $ 108,809,604       108,809,604   $ 103,219,124
Exercises warrants           $ 2,672,500  
Subsequent Event [Member]                
Subsequent Event [Line Items]                
Exercises warrants $ 800,000              
v3.24.2.u1
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 701,103 80,431
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares [1] 689,293 67,835
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 9,671 10,243
Series A Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 72 286
Series B Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 2,067 2,067
[1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.
v3.24.2.u1
Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - shares
Jun. 30, 2024
Jun. 30, 2023
Inflamacore, LlC License Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Warrants to purchase common shares 342 342
v3.24.2.u1
Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
L&F milestone payment liability $ 500,000
Payroll accrual 731,717 668,803
Other accrued expenses 21,969 41,969
Bonus accrual 917,375 536,500
Registration delay liability [1] 7,261 7,261
Total accrued expenses and other current liabilities $ 1,678,322 $ 1,754,533
[1] See Note 7 - Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.
v3.24.2.u1
Schedule of Income Taxes Expense Effective Tax Rate (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Tax Disclosure [Abstract]        
Income tax (expense) benefit $ (9,707) $ 7,812,226 $ (9,707) $ 8,859,277
Effective tax rate     (0.17%) 9.70%
v3.24.2.u1
Income Taxes (Details Narrative)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Income Tax Disclosure [Abstract]    
Effective tax rate (0.17%) 9.70%
v3.24.2.u1
Schedule of Right of Use Assets and Liabilities (Details) - USD ($)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]    
Operating cash flows used in operating activities $ 8,656 $ 49,130
Operating leases
Weighted average remaining lease term   7 months 2 days
Weighted average discount rate   6.50%
v3.24.2.u1
Commitments and Contingencies (Details Narrative)
 3 Months Ended 6 Months Ended
Jul. 01, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jan. 30, 2024
USD ($)
Jan. 15, 2024
USD ($)
Mar. 29, 2023
USD ($)
shares
Feb. 28, 2023
USD ($)
Jan. 18, 2019
USD ($)
ft²
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Invoices from a vendor $ 162,800 $ 992,176                  
Number of operating lease square feet | ft²             3,500        
Lease cost             $ 89,000        
Operating lease rent expense             $ 497,000 $ 43,271   $ 84,743  
Lessee, Lease, Description [Line Items]                      
Operating lease asset amortization               $ 0 $ 38,783 $ 7,839 $ 77,198
Lease Commitment [Member]                      
Operating lease rent expense       $ 112,064              
License Agreement [Member] | L&F Research LLC [Member]                      
Milestone payment description           the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).          
License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]                      
Debt forgiveness           $ 351,579          
Cash payment         $ 648,421 648,421          
Reclassification shares of common stock | shares         188            
Reclassification shares of common stock value classified as temporary to permanent equity         $ 331,331            
License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member]                      
Cash payment     $ 500,000     $ 500,000          
Maturity date           Jan. 31, 2024          
Net proceeds from issuance of equity capital           $ 30,000,000          
v3.24.2.u1
Schedule of Stock Options Granted (Details) - $ / shares
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Fair value of common stock on date of grant $ 0.44  
Risk free interest rate 3.76%  
Expected term (years) 6 years 6 years
Expected volatility 122.00%  
Expected dividends 0.00% 0.00%
Minimum [Member]    
Fair value of common stock on date of grant   $ 0.44
Risk free interest rate   3.53%
Expected volatility   120.00%
Maximum [Member]    
Fair value of common stock on date of grant   $ 2.23
Risk free interest rate   4.27%
Expected volatility   123.00%
v3.24.2.u1
Schedule of Stock Option Activity (Details)
 6 Months Ended
Jun. 30, 2024
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of options, outstanding beginning balance | shares 10,243
Weighted average exercise price, beginning balance | $ / shares $ 2,218.51
Number of options, granted | shares
Weighted average exercise price, granted | $ / shares
Number of options, exercised | shares
Weighted average exercise price, exercised | $ / shares
Number of options, forfeited | shares (572)
Weighted average exercise price, forfeited | $ / shares $ 1,760.50
Number of options, outstanding ending balance | shares 9,671
Weighted average exercise price, ending balance | $ / shares $ 2,245.60
Weighted average remaining life in years, outstanding 5 years 9 months 18 days
Aggregate intrinsic value, ending balance | $
Number of options, exercisable ending balance | shares 6,823
Weighted average exercise price, Exercisable | $ / shares $ 2,979.56
Weighted average remaining life in years, exercisable 5 years 10 months 24 days
Aggregate intrinsic value, exercisable | $
v3.24.2.u1
Schedule of Information Related to Stock Options (Details)
 6 Months Ended
Jun. 30, 2024
$ / shares
shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, Number of options 9,671
Options exercisable, weighted average remaining life in years 5 years 10 months 24 days
Options exercisable, Number of options 6,823
Exercise Price One [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 152.50
Options outstanding, Number of options 4,157
Options exercisable, weighted average remaining life in years 8 years 10 months 24 days
Options exercisable, Number of options 1,674
Exercise Price Two [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 738.50
Options outstanding, Number of options 286
Options exercisable, weighted average remaining life in years 8 years 7 months 6 days
Options exercisable, Number of options 95
Exercise Price Three [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 791.00
Options outstanding, Number of options 38
Options exercisable, weighted average remaining life in years 8 years 8 months 12 days
Options exercisable, Number of options 12
Exercise Price Four [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 1,760.50
Options outstanding, Number of options 1,338
Options exercisable, weighted average remaining life in years 2 years 3 months 18 days
Options exercisable, Number of options 1,338
Exercise Price Five [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 3,965.50
Options outstanding, Number of options 37
Options exercisable, weighted average remaining life in years 8 years
Options exercisable, Number of options 37
Exercise Price Six [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 4,053.00
Options outstanding, Number of options 2,095
Options exercisable, weighted average remaining life in years 4 years 9 months 18 days
Options exercisable, Number of options 2,095
Exercise Price Seven [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding, exercise price | $ / shares $ 5,726.00
Options outstanding, Number of options 1,720
Options exercisable, weighted average remaining life in years 6 years 10 months 24 days
Options exercisable, Number of options 1,572
v3.24.2.u1
Summary of Warrant Activity (Details)
 6 Months Ended
Jun. 30, 2024
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of warrants, outstanding beginning balance | shares 903,320 [1]
Weighted average exercise price, beginning balance | $ / shares $ 123.44 [1]
Number of warrants, granted | shares
Weighted average exercise price, granted | $ / shares
Number of warrants, forfeited | shares (227)
Weighted average exercise price, forfeited | $ / shares $ 4,053.00
Number of warrants, exercised | shares (213,800) [2]
Weighted average exercise price, exercised | $ / shares $ 12.50 [2]
Number of warrants, outstanding ending balance | shares 689,293
Weighted average exercise price, ending balance | $ / shares $ 156.64
Weighted average remaining life in years, outstanding 3 years 5 months 1 day
Aggregate intrinsic value, ending balance | $
Number of warrants, exercisable ending balance | shares 689,093
Weighted average exercise price, Exercisable | $ / shares $ 156.17
Weighted average remaining life in years, exercisable 3 years 5 months 1 day
Aggregate intrinsic value, exercisable | $
[1] Warrants outstanding exclude 131,500 December 2023 Pre-Funded Warrants outstanding with an exercise price of $0.001.
[2] Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.
v3.24.2.u1
Summary of Warrant Activity (Details) (Parenthetical)
 6 Months Ended
Jun. 30, 2024
$ / shares
shares
Class of Warrant or Right [Line Items]  
Number of warrants, outstanding 9,671
Number of warrants, exercised 213,800 [1]
December 2023 Pre-Funded Warrants [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants, outstanding 131,500
Warrants exercise price | $ / shares $ 0.001
Number of warrants, exercised 131,500
Exercise price | $ / shares $ 0.001
[1] Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.
v3.24.2.u1
Schedule of Information Related to Stock Warrants (Details) - $ / shares
 6 Months Ended
Jun. 30, 2024
Dec. 31, 2023
 [1]
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Number of warrants, outstanding 689,293 903,320
Number of warrants, exercisable 689,093  
Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Number of warrants, outstanding 689,293  
Warrant exercisable, weighted average remaining life in years 3 years 5 months 1 day  
Number of warrants, exercisable 689,093  
Exercise Price One [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 12.50  
Number of warrants, outstanding 586,200  
Warrant exercisable, weighted average remaining life in years 3 years 3 months 29 days  
Number of warrants, exercisable 586,200  
Exercise Price Two [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 47.50  
Number of warrants, outstanding 20,347  
Warrant exercisable, weighted average remaining life in years 4 years 8 months 12 days  
Number of warrants, exercisable 20,347  
Exercise Price Three [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 57.75  
Number of warrants, outstanding 19,965  
Warrant exercisable, weighted average remaining life in years 4 years 7 days  
Number of warrants, exercisable 19,965  
Exercise Price Four [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 350.00  
Number of warrants, outstanding 27,551  
Warrant exercisable, weighted average remaining life in years 3 years 9 months 29 days  
Number of warrants, exercisable 27,551  
Exercise Price Five [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 700.00  
Number of warrants, outstanding 13,944  
Warrant exercisable, weighted average remaining life in years 3 years 5 months 12 days  
Number of warrants, exercisable 13,944  
Exercise Price Six [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 1,760.50  
Number of warrants, outstanding 300  
Warrant exercisable, weighted average remaining life in years 2 months 8 days  
Number of warrants, exercisable 100  
Exercise Price Seven [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 2,415.00  
Number of warrants, outstanding 3,651  
Warrant exercisable, weighted average remaining life in years 3 years 5 months 12 days  
Number of warrants, exercisable 3,651  
Exercise Price Eight [Member] | Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Weighted average exercise price, outstanding $ 4,025.00  
Number of warrants, outstanding 17,335  
Warrant exercisable, weighted average remaining life in years 3 years 5 months 12 days  
Number of warrants, exercisable 17,335  
[1] Warrants outstanding exclude 131,500 December 2023 Pre-Funded Warrants outstanding with an exercise price of $0.001.
v3.24.2.u1
Stockholders’ Permanent and Temporary Equity (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Apr. 25, 2024
Mar. 06, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Feb. 23, 2024
Feb. 20, 2023
Subsidiary, Sale of Stock [Line Items]                
Reverse stock split the Company effected the 2024 Reverse Split. Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock.              
Stock based compensation expense     $ 160,664 $ 365,742 $ 384,237 $ 653,203    
Unrecognized stock-based compensation expense     643,224   $ 643,224      
weighted average period         1 year 4 months 24 days      
Gross proceeds warrants         $ 2,672,500    
Percentage of registration delay payments               1.50%
Effectiveness failure interest rate               2.00%
Accrued registration delay payments         7,261      
Pre Funded Warrants [Member] | Investor [Member]                
Subsidiary, Sale of Stock [Line Items]                
Warrants to purchase common shares             131,500  
Warrant exercise price             $ 0.001  
Warrants exercised on cashless basis             131,481  
December 2023 Offering [Member]                
Subsidiary, Sale of Stock [Line Items]                
Warrants to purchase common shares   213,800            
Warrant exercise price   $ 12.50            
Gross proceeds warrants   $ 2,672,500            
Research and Development Expense [Member]                
Subsidiary, Sale of Stock [Line Items]                
Stock based compensation expense     15,447 109,066 30,895 158,521    
General and Administrative Expense [Member]                
Subsidiary, Sale of Stock [Line Items]                
Stock based compensation expense     145,217 $ 256,676 $ 353,342 $ 494,682    
Marketing Agreements [Member]                
Subsidiary, Sale of Stock [Line Items]                
Shares issued for services         9,000      
Prepaid expense fair value of shares     $ 79,200   $ 79,200      
v3.24.2.u1
Subsequent Events (Details Narrative) - USD ($)
 6 Months Ended
Aug. 01, 2024
Jun. 30, 2024
Aug. 09, 2024
Subsequent Event [Line Items]      
Grant of warrants   5 years 10 months 24 days  
Subsequent Event [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Warrants to purchase common shares     239,300
Ownership limitations     194,300
Unissued shares of common stock 45,000    
December 2023 Offering [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Exercise price $ 3.46    
Financial advisor fees $ 50,000    
December 2023 Offering [Member] | Subsequent Event [Member] | Common Stock One [Member]      
Subsequent Event [Line Items]      
New issuance of warrants 392,000    
Grant of warrants 5 years    
Warrant exercise price $ 3.46    
December 2023 Offering [Member] | Subsequent Event [Member] | Common Stock Two [Member]      
Subsequent Event [Line Items]      
New issuance of warrants 86,600    
Grant of warrants 18 months    
Warrant exercise price $ 3.46    
December 2023 Offering [Member] | Subsequent Event [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Warrants to purchase common shares 239,300    
Gross proceeds $ 827,978    
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024 Haga Click aquí para más Gráficas ZyVersa Therapeutics.
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024 Haga Click aquí para más Gráficas ZyVersa Therapeutics.